Advancing Health Equity for Lupus Patients in Wisconsin: How a Care Continuum and Community Stakeholders Can Inform Interventions to Close Disparities Gaps

Outcome Report
Awarded in 2020
Updated Oct 22, 2025

At a Glance

Gaps in lupus care contribute to higher kidney failure, more early death, and worse lupus damage in U.S. patients who are Black or poor. This project used new data analysis methods to study and identify steps in lupus care with the largest impact on patient health. Health care and patient partners then helped select, adapt, and pilot test strategies to reduce health disparities and improve outcomes.

The Challenge

Lupus is one of the most common autoimmune diseases, causing lifelong burden for 1.5 million U.S. residents and 28,000 Wisconsin residents. Currently, gaps in care for people with lupus contribute to more kidney failure, more cases of early death, and greater disease damage. Notably, in the U.S., those with lupus who are Black suffer greater disease burden when compared to other countries, likely indicating disparities in the U.S. health care system. Research shows that similar care gaps and negative health consequences experienced by people with HIV were reduced by more than 20 percent through targeting key steps in the healthcare process.

Project Goals

The goal of this project was to improve lupus care by identifying modifiable gaps in the lupus care continuum and adapting evidence-based HIV interventions in order to reduce disparities in lupus outcomes.

Results

An analysis of medical records from three Wisconsin health care systems representing diverse populations revealed almost 30 percent higher risk of serious disease damage for those living in areas of greater disadvantage as well as a higher risk of new damage among Black patients with lower hydroxychloroquine (HCQ) adherence. Using national Medicare data, the research team published a new statistical method that uncovered if patients stay in care or stay on HCQ, they most effectively close gaps in medical outcomes. The team convened patients, providers, experts and public health advocates to identify feasible and effective interventions. In collaboration with UW Health, they developed an electronic health record reporting workbench for clinics that allows them to easily identify and reach out to patients with lupus who are missing visits and labs.

Looking to the Future

This work will be expanded through a $2.4 million Department of Defense grant, which seeks to support HCQ adherence and leverage the lupus reporting workbench to include eye screenings.

research icon: microscope and stethoscope
Collaborative Health Sciences Program

UW Innovations in Malignancy Personalized Advanced Cell Therapies (UW-IMPACT)


Outcome Report
Awarded in 2018
This project, led by Jacques Galipeau, MD, aimed to to generate the data needed to secure Investigative New Drug licenses from the Food and Drug Administration (FDA) to use personalized GIFT4 B cells to treat cancer as part of first-in-human clinical trials at the UW Carbone Cancer Center. Previous work enabled researchers to convert normal mouse B cells to cancer-killing cells by treating them with a synthetic cell-signaling protein called GIFT4, and the resulting cells were able to initiate an anti-tumor immune response even in the absence of defined tumor markers. In this work, researchers tested these GIFT4 B cells in mice with prostate and neuroblastoma tumors to see if the cells could improve the immune system’s ability to fight cancer. The researchers made significant progress toward their goal. They found that B cells, when grown with dendritic cells and exposed to GIFT4 protein, could activate T cells which then target tumors. These findings demonstrated the importance of understanding B cell-dendritic cell interactions to advance cancer vaccine development. Additionally, combining GIFT4 B cells with radiation and immunotherapies improved survival, highlighting the efficacy of multifaceted therapies in targeting cancer. Overall, these results have the potential to enhance cell therapies leading to more effective treatment strategies for cancer in the future.